Compare Stocks: SCNX, SCLX, GRCE, and VERU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.12 -1.9%	$2.17	$1.79 ▼ $5.18	$45.44M	0.44	148,773 shs	80,176 shs
SCLX Scilex	$4.89 -1.0%	$5.99	$4.20 ▼ $30.90	$41.96M	1.65	28,278 shs	42,769 shs
SCNX Scienture	$0.28 -3.3%	$0.38	$0.24 ▼ $2.60	$11.78M	3.25	1.53 million shs	413,656 shs
VERU Veru	$2.54 +1.2%	$2.50	$2.05 ▼ $7.33	$42.80M	-1.17	206,539 shs	115,801 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	-1.85%	+0.47%	-1.40%	-10.74%	-31.61%
SCLX Scilex	-1.01%	-2.98%	-12.83%	-31.22%	-82.90%
SCNX Scienture	-3.34%	-11.52%	-27.78%	-22.99%	-67.68%
VERU Veru	+1.20%	+5.39%	-9.29%	-15.61%	-26.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.12 -1.9%	$2.17	$1.79 ▼ $5.18	$45.44M	0.44	148,773 shs	80,176 shs
SCLX Scilex	$4.89 -1.0%	$5.99	$4.20 ▼ $30.90	$41.96M	1.65	28,278 shs	42,769 shs
SCNX Scienture	$0.28 -3.3%	$0.38	$0.24 ▼ $2.60	$11.78M	3.25	1.53 million shs	413,656 shs
VERU Veru	$2.54 +1.2%	$2.50	$2.05 ▼ $7.33	$42.80M	-1.17	206,539 shs	115,801 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	-1.85%	+0.47%	-1.40%	-10.74%	-31.61%
SCLX Scilex	-1.01%	-2.98%	-12.83%	-31.22%	-82.90%
SCNX Scienture	-3.34%	-11.52%	-27.78%	-22.99%	-67.68%
VERU Veru	+1.20%	+5.39%	-9.29%	-15.61%	-26.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRCE Grace Therapeutics	2.00	Hold	$6.00	183.02% Upside
SCLX Scilex	1.00	Sell	N/A	N/A
SCNX Scienture	2.00	Hold	$1.50	440.74% Upside
VERU Veru	2.33	Hold	$24.50	864.57% Upside

Current Analyst Ratings Breakdown

Latest SCNX, SCLX, GRCE, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/21/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/18/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/21/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
SCLX Scilex	$30.25M	1.37	N/A	N/A	($24.94) per share	-0.20
SCNX Scienture	$430K	26.49	N/A	N/A	$1.73 per share	0.16
VERU Veru	$16.89M	2.56	N/A	N/A	$1.25 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
SCLX Scilex	-$358.73M	-$49.70	N/A	N/A	N/A	-1,414.57%	N/A	-147.00%	12/2/2026 (Estimated)
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)

Latest SCNX, SCLX, GRCE, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/14/2026	Q2 2026	SCLX Scilex	-$0.1813	-$16.65	-$16.4687	-$16.65	$16.00 million	$7.64 million
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRCE Grace Therapeutics	N/A	11.47	11.47
SCLX Scilex	N/A	0.07	0.06
SCNX Scienture	0.15	3.04	2.97
VERU Veru	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRCE Grace Therapeutics	6.08%
SCLX Scilex	69.67%
SCNX Scienture	5.68%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
GRCE Grace Therapeutics	10.84%
SCLX Scilex	4.50%
SCNX Scienture	21.39%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRCE Grace Therapeutics	5	21.04 million	18.76 million	N/A
SCLX Scilex	34	8.49 million	8.11 million	No Data
SCNX Scienture	9	41.06 million	32.28 million	N/A
VERU Veru	230	17.05 million	14.63 million	Optionable

SCNX, SCLX, GRCE, and VERU Headlines

Recent News About These Companies

Veru (NASDAQ:VERU) Stock Rating Upgraded by Wall Street Zen

September 19, 2026 | americanbankingnews.com

Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

September 8, 2026 | rttnews.com

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...

September 8, 2026 | finance.yahoo.com

Veru refocuses sabizabulin on post-daraxonrasib oncology

September 8, 2026 | tipranks.com

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

September 8, 2026 | quiverquant.comQ

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Veru (VERU) Q3 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10, 2026 | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10, 2026 | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10, 2026 | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026 | globenewswire.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, SCLX, GRCE, and VERU Company Descriptions

Grace Therapeutics NASDAQ:GRCE

$2.12 -0.04 (-1.85%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.17 +0.05 (+2.36%)

As of 09/25/2026 07:30 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Scilex NASDAQ:SCLX

$4.89 -0.05 (-1.01%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.88 0.00 (-0.10%)

As of 09/25/2026 07:55 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Scienture NASDAQ:SCNX

$0.28 -0.01 (-3.34%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.27 0.00 (-1.23%)

As of 09/25/2026 06:58 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

Veru NASDAQ:VERU

$2.54 +0.03 (+1.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.52 -0.02 (-0.59%)

As of 09/25/2026 07:46 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, SCLX, GRCE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, SCLX, GRCE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, SCLX, GRCE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, SCLX, GRCE, and VERU Company Descriptions

Grace Therapeutics NASDAQ:GRCE

Scilex NASDAQ:SCLX

Scienture NASDAQ:SCNX

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, SCLX, GRCE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, SCLX, GRCE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, SCLX, GRCE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, SCLX, GRCE, and VERU Company Descriptions

Grace Therapeutics NASDAQ:GRCE

Scilex NASDAQ:SCLX

Scienture NASDAQ:SCNX

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools